Related Experiment Video
Updated: May 24, 2025

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
Poor reporting quality and high proportion of missing data in economic evaluations alongside pragmatic trials: a
Yu Xin1, Ruomeng Song2, Jun Hao3,4,5
1Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, China.
Background:
Lack of data integrity is a common problem in randomized clinical trials and is more serious in economic evaluations conducted alongside explanatory clinical trials. Despite pragmatic randomized controlled trials (pRCTs) becoming recognized as the best design for economic evaluations, information on the proportion, handling approaches, and reporting quality of missing data in pRCTs-based economic evaluations remains limited. This study aimed to investigate the quantity and reporting quality of missing data in economic evaluations conducted alongside pragmatic clinical trials.
Methods:
In this cross-sectional survey, data were extracted from PubMed and OVID (Embase, CENTRAL, HTA database, and NHS EED) from January 1, 2010, to April 24, 2022. Economic evaluations conducted alongside pRCTs were included. Two independent reviewer groups identified relevant articles, and data were extracted by three groups comprising two reviewers each. Descriptive analyses were performed to assess the characteristics of the included studies, missingness in the included studies, and handling of missing data.
Results:
Overall, 715 studies were identified, of which 152 met the inclusion criteria. In total, 113, 119, and 132 articles reported missing data, costs, and effects, respectively. More than 50% (58/113) of the articles reported the proportion or quantity of overall missingness, and 64.71% and 54.55% reported missing costs and effects, respectively. The proportion of missingness of < 5% in the overall group was 3.45%, whereas the proportions of missing costs and effects were both < 10% (5.26% vs. 8.45%, respectively). In terms of the proportion of missing data, the overall missingness rate was 30.22% in 58 studies, whereas the median proportion of missing data was slightly higher than that of missing effects (30.92% vs. 27.78%). Of the included studies, 56 (36.84%) conducted a sensitivity analysis on handling missing data. Of these, 12.50% reported missing mechanisms, and 83.93% examined handling methods.
Conclusions:
Insufficient description and reporting of missing data, along with a high proportion of missing data in pRCT-based economic evaluations, could decrease the reliability and extrapolation of conclusions, leading to misleading decision-making.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bias in Epidemiological Studies
Bias
In statistics, a sampling bias is created when a sample is collected from a population, and some members of the population are not as likely to be chosen as others (remember, each member...
Clinical Trials: Overview
Regression Toward the Mean
Blinding